Yet while SPY's 14% return is certainly impressive��specially for just six months��his pales in comparison to what investors have seen in a few choice sectors. These market segments have risen roughly twice as much as what we have seen in the S&P 500 in the same time period, suggesting that these have been excellent picks for investors during this six month time frame (read 3 Top Ranked Mid Cap ETFs to Buy Now).
Plus, these sectors appear to be well-positioned in the second half of the year, as the trends that propelled the space higher to begin 2013 are still in place. For this reason, investors might want to take a closer look at the top performing ETFs in the best sectors below, as they could provide for some great ideas to close out 2013 as well.
Best India Stocks To Watch For 2016: Questerre Energy Corp (QEC)
Questerre Energy Corporation (Questerre) is engaged in the exploration for, and the development, production and acquisition of oil and gas projects, particularly shale oil and gas. Questerre holds assets in British Columbia, Alberta, Saskatchewan, Manitoba and Quebec. Questerre has three core areas where it conducts the majority of its activity: Oil Shale Mining, Western Canada and the St. Lawrence Lowlands, Quebec. The Company has a 100% interest in two licenses covering approximately 100,000 acres in the Pasquia Hills area of east central Saskatchewan. The Antler area is approximately 200 kilometers from Regina in southeast Saskatchewan. The Vulcan area in Southern Alberta is prospective for natural gas and oil in multiple horizons. The Lowlands are situated in Quebec south of the St. Lawrence River between Montreal and Quebec City. As at December 31, 2011, the Company had an interest in 98 gross (55.2 net) producing and 40 gross (17.8 net) non-producing oil and natural gas. Advisors' Opinion:- [By James E. Brumley]
What do Questerre Energy Corp. (TSE:QEC) and Crescent Point Energy Corp. (TSE:CPG) know about oil in Saskatchewan that Centor Energy Inc. (OTCBB:CNTO) doesn't? Absolutely nothing. All three companies know there's oil in the southern part of the Canadian province, and they know exactly how to go get it. The only difference between QEC, CPG, and CNTO is, Questerre Energy and Crescent Point Energy are further along the development of their operations there than Centor Energy.
5 Best Mid Cap Stocks To Buy Right Now: Stanley Furniture Company Inc.(STLY)
Stanley Furniture Company, Inc., together with its subsidiaries, designs, manufactures, and imports wood furniture products for the residential market. It offers a line of adult furniture products comprising dining, bedroom, home office, home entertainment, and accent items under the Stanley Furniture brand name; and children?s furniture product line under the brand name of Young America. The company provides its products under various design categories, including traditional, continental, contemporary, transitional, and cottage designs. Stanley Furniture Company, Inc. sells its furniture products through independent sales representatives to independent furniture stores, interior designers, smaller specialty retailers, regional furniture chains, buying clubs, and e-tailers in the United States. Stanley Furniture Company, Inc. was founded in 1924 and is based in High Point, North Carolina.
Advisors' Opinion:- [By Tom Bemis]
Few major companies are reporting after Monday�� bell. Results are expected from Destiny Media Technologies (DSNY) �, Stanley Furniture Co. (STLY) � and Peregrine Pharmaceuticals. (PPHM) �.
5 Best Mid Cap Stocks To Buy Right Now: First Trust Ise Global Engineering And Construction Index Fund (FLM)
First Trust ISE Global Engineering and Construction Index Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the ISE Global Engineering and Construction Index (the Index). The Fund is a series of the First Trust Exchange-Traded Fund II, an investment company and an exchange-traded index fund. The Index is developed and owned by the International Securities Exchange, LLC (ISE or Index Provider), in consultation with Standard & Poor's, a Division of The McGraw-Hill Companies, Inc., which calculates and maintains the Index. The Index specifically targets companies that are engaged in civil and capital projects, such as infrastructure, utilities, transportation, telecommunications, commercial, residential and commerce facilities, and whose roles are within the engineering, designing, planning, consulting, project managing and/or constructing of these projects. First Trust Advisors L.P. is the investment adviser for the Fund. Advisors' Opinion:- [By John Udovich]
Mid cap infrastructure construction stock Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 7.23% after being trashed in an article by an apparent�short seller posted on Seeking Alpha, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks like Jacobs Engineering Group Inc (NYSE: JEC), KBR, Inc (NYSE: KBR) and First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM).
- [By John Udovich]
Small cap building materials stock NCI Building Systems Inc (NYSE: NCS) fell yesterday after announcing a share offering plus its investors have (so-far) missed out on any ��ecovery��in construction���meaning it might be time to take a closer look at the stock along with potential performance benchmarks like the PowerShares Dynamic Building & Construction ETF (NYSEARCA: PKB) and the First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM)���both of which have had decent returns in recent years.
5 Best Mid Cap Stocks To Buy Right Now: Biota Pharmaceuticals Inc (BOTA)
Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.
The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.
Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.
PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.
Advisors' Opinion:- [By gurujx]
Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42
The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.
No comments:
Post a Comment